| Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial C Gridelli, F Perrone, C Gallo, S Cigolari, A Rossi, F Piantedosi, ... Journal of the National Cancer Institute 95 (5), 362-372, 2003 | 1049 | 2003 |
| Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non—small-cell lung cancer receiving … P Maione, F Perrone, C Gallo, L Manzione, FV Piantedosi, S Barbera, ... Journal of Clinical Oncology 23 (28), 6865-6872, 2005 | 568 | 2005 |
| Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ... The Lancet Oncology 20 (12), 1655-1669, 2019 | 530 | 2019 |
| Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry M Ligor, T Ligor, A Bajtarevic, C Ager, M Pienz, M Klieber, H Denz, ... Clinical chemistry and laboratory medicine 47 (5), 550-560, 2009 | 323 | 2009 |
| First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non–small-cell lung cancer: the TORCH randomized trial C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts, V Gebbia, P Maione, ... Journal of Clinical Oncology 30 (24), 3002-3011, 2012 | 276 | 2012 |
| A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study C Gridelli, C Gallo, M Di Maio, E Barletta, A Illiano, P Maione, S Salvagni, ... British Journal of Cancer 91 (12), 1996-2004, 2004 | 203 | 2004 |
| Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer M Di Maio, C Gridelli, C Gallo, L Manzione, L Brancaccio, S Barbera, ... British journal of cancer 90 (12), 2288-2296, 2004 | 184 | 2004 |
| Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial L Landi, R Chiari, M Tiseo, F D'Incà, C Dazzi, A Chella, A Delmonte, ... Clinical cancer research 25 (24), 7312-7319, 2019 | 163 | 2019 |
| Natural history of non-small-cell lung cancer with bone metastases D Santini, S Barni, S Intagliata, A Falcone, F Ferraù, D Galetta, L Moscetti, ... Scientific reports 5 (1), 1-9, 2015 | 121 | 2015 |
| Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer L Landi, F D’Incà, A Gelibter, R Chiari, F Grossi, A Delmonte, A Passaro, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 115 | 2019 |
| Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study C Gridelli, C Gallo, A Ceribelli, V Gebbia, T Gamucci, F Ciardiello, ... The lancet oncology 8 (6), 500-512, 2007 | 112 | 2007 |
| Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer C Gridelli, P Maione, V Castaldo, A Rossi British journal of cancer 89 (10), 1827-1829, 2003 | 91 | 2003 |
| Italian nivolumab expanded access program in nonsquamous non–small cell lung cancer patients: results in never-smokers and EGFR-mutant patients MC Garassino, AJ Gelibter, F Grossi, R Chiari, HS Parra, S Cascinu, ... Journal of Thoracic Oncology 13 (8), 1146-1155, 2018 | 86 | 2018 |
| Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations C Pinto, S Novello, V Torri, A Ardizzoni, PG Betta, PA Bertazzi, ... Cancer treatment reviews 39 (4), 328-339, 2013 | 81 | 2013 |
| Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations F Passiglia, F Cappuzzo, O Alabiso, AC Bettini, P Bidoli, R Chiari, ... British journal of cancer 120 (1), 57-62, 2019 | 75 | 2019 |
| Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+ gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by … V Gebbia, D Galetta, M Caruso, F Verderame, G Pezzella, M Valdesi, ... Lung Cancer 39 (2), 179-189, 2003 | 73 | 2003 |
| Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis MC Garassino, V Torri, G Michetti, ML Dico, N La Verde, S Aglione, ... Lung Cancer 72 (3), 378-383, 2011 | 72 | 2011 |
| ROS1-rearranged non–small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS) R Chiari, B Ricciuti, L Landi, AM Morelli, A Delmonte, G Spitaleri, ... Clinical Lung Cancer 21 (1), 15-20, 2020 | 70 | 2020 |
| Cisplatin/pemetrexed followed by maintenance pemetrexed versus carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: the … D Galetta, S Cinieri, S Pisconti, V Gebbia, A Morabito, N Borsellino, ... Clinical lung cancer 16 (4), 262-273, 2015 | 63 | 2015 |
| Biological role of NHERF1 protein expression in breast cancer A Mangia, A Chiriatti, A Bellizzi, A Malfettone, B Stea, FA Zito, SJ Reshkin, ... Histopathology 55 (5), 600-608, 2009 | 61 | 2009 |
Francesco PerroneIstituto Nazionale Tumori di Napoli在 istitutotumori.na.it 的电子邮件经过验证
